Journal article
Mucormycosis in Australia: contemporary epidemiology and outcomes
KJ Kennedy, K Daveson, MA Slavin, SJ van Hal, TC Sorrell, A Lee, DJ Marriott, B Chapman, CL Halliday, K Hajkowicz, E Athan, N Bak, E Cheong, CH Heath, CO Morrissey, S Kidd, R Beresford, C Blyth, TM Korman, JO Robinson Show all
Clinical Microbiology and Infection | ELSEVIER SCI LTD | Published : 2016
Abstract
Mucormycosis is the second most common cause of invasive mould infection and causes disease in diverse hosts, including those who are immuno-competent. We conducted a multicentre retrospective study of proven and probable cases of mucormycosis diagnosed between 2004–2012 to determine the epidemiology and outcome determinants in Australia. Seventy-four cases were identified (63 proven, 11 probable). The majority (54.1%) were caused by Rhizopus spp. Patients who sustained trauma were more likely to have non-Rhizopus infections relative to patients without trauma (OR 9.0, p 0.001, 95% CI 2.1–42.8). Haematological malignancy (48.6%), chemotherapy (42.9%), corticosteroids (52.7%), diabetes mellit..
View full abstractGrants
Awarded by Merck
Funding Acknowledgements
The authors thank Pfizer Australia, Gilead Sciences Inc. and MSD Australia for their financial support of this study.